Worsening of endogenous Candida albicans endophthalmitis during therapy with intravenous lipid complex amphotericin B.
Virata
S R
SR
Department of Ophthalmology, University of North Carolina School of Medicine, Chapel Hill, USA.
Kylstra
J A
JA
Brown
J C
JC
Wohl
D A
DA
Cohen
M S
MS
D000328:Adult; D000666:Amphotericin B / Q000627:therapeutic use*; D000935:Antifungal Agents / Q000627:therapeutic use*; D002177:Candidiasis / Q000188:drug therapy*; D004338:Drug Combinations; D009877:Endophthalmitis / Q000188:drug therapy* / Q000382:microbiology; D015821:Eye Infections, Fungal / Q000188:drug therapy* / Q000382:microbiology; D005260:Female; D006801:Humans; D007262:Infusions, Intravenous; D010713:Phosphatidylcholines / Q000627:therapeutic use*; D010715:Phosphatidylglycerols / Q000627:therapeutic use*
D000935:Antifungal Agents; D004338:Drug Combinations; D010713:Phosphatidylcholines; D010715:Phosphatidylglycerols; C068538:liposomal amphotericin B; D000666:Amphotericin B